nach oben

Erschienen in:

01.07.2013

Heart rate reduction in heart failure: ivabradine or beta blockers?

Erschienen in: Heart Failure Reviews | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Ivabradine, a selective I f current inhibitor, decreasing the heart rate in those with sinus rhythm, has been added to the most recent European guidelines on heart failure. It is indicated in addition to beta blockers in patients with decreased left ventricular ejection fraction and sinus rate of over 70 beats per minute. Several well-designed studies including the BEAUTIFUL and the SHIFT trials demonstrated clear benefits of ivabradine in symptomatic patients, both with angina and with heart failure, with left ventricular systolic dysfunction. The main objective of this review is to provide a comprehensive summary of data on ivabradine, and to discuss the potential role of this new agent in the spectrum of modern therapeutics for heart failure.

Palatini P, Casiglia E, Julius S, Pessina AC (1999) High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 159(6):585–592PubMedCrossRef

Jouven X, Empana JP, Escolano S, Buyck JF, Tafflet M, Desnos M et al (2009) Relation of heart rate at rest and long-term (>20 years) death rate in initially healthy middle-aged men. Am J Cardiol 103(2):279–283. doi:10.1016/j.amjcard.2008.08.071 PubMedCrossRef

Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA (1987) Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 113(6):1489–1494PubMedCrossRef

Cucherat M (2007) Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 28(24):3012–3019. doi:10.1093/eurheartj/ehm489 PubMedCrossRef

Packer DL, Bardy GH, Worley SJ, Smith MS, Cobb FR, Coleman RE et al (1986) Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 57(8):563–570PubMedCrossRef

Thackray SD, Ghosh JM, Wright GA, Witte KK, Nikitin NP, Kaye GC et al (2006) The effect of altering heart rate on ventricular function in patients with heart failure treated with beta-blockers. Am Heart J 152(4):713 e719-713. doi:10.1016/j.ahj.2006.07.007 CrossRef

Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM (1997) Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12):2660–2667PubMedCrossRef

Poole-Wilson PA, Uretsky BF, Thygesen K, Cleland JG, Massie BM, Ryden L (2003) Mode of death in heart failure: findings from the ATLAS trial. Heart 89(1):42–48PubMedCrossRef

Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV et al (1997) Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina-Grupo de Estudios Multicentricos en Argentina. J Am Coll Cardiol 29(6):1199–1205PubMedCrossRef

10.

Kapoor JR, Heidenreich PA (2010) Heart rate predicts mortality in patients with heart failure and preserved systolic function. J Card Fail 16(10):806–811. doi:10.1016/j.cardfail.2010.04.013 PubMedCrossRef

11.

Thollon C, Bidouard JP, Cambarrat C, Lesage L, Reure H, Delescluse I et al (1997) Stereospecific in vitro and in vivo effects of the new sinus node inhibitor (+)-S 16257. Eur J Pharmacol 339(1):43–51PubMedCrossRef

12.

DiFrancesco D, Camm JA (2004) Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 64(16):1757–1765PubMedCrossRef

13.

Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF et al (2006) Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 61(2):127–137. doi:10.1111/j.1365-2125.2005.02544.x PubMedCrossRef

14.

Manz M, Reuter M, Lauck G, Omran H, Jung W (2003) A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100(3):149–155. doi:10.1159/000073933 PubMedCrossRef

15.

Camm AJ, Lau CP (2003) Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R D 4(2):83–89PubMedCrossRef

16.

Tendera M, Talajic M, Robertson M, Tardif JC, Ferrari R, Ford I et al (2011) Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 107(6):805–811. doi:10.1016/j.amjcard.2010.10.065 PubMedCrossRef

17.

Borer JS, Fox K, Jaillon P, Lerebours G (2003) Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107(6):817–823PubMedCrossRef

18.

Tardif JC, Ponikowski P, Kahan T (2009) Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 30(5):540–548. doi:10.1093/eurheartj/ehn571 PubMedCrossRef

19.

De Ferrari GM, Mazzuero A, Agnesina L, Bertoletti A, Lettino M, Campana C et al (2008) Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 10(6):550–555. doi:10.1016/j.ejheart.2008.04.005 PubMedCrossRef

20.

Ceconi C, Cargnoni A, Francolini G, Parinello G, Ferrari R (2009) Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc Res 84(1):72–82. doi:10.1093/cvr/cvp158 PubMedCrossRef

21.

Ceconi C, Comini L, Suffredini S, Stillitano F, Bouly M, Cerbai E et al (2011) Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. Am J Physiol Heart Circ Physiol 300(1):H366–H373. doi:10.1152/ajpheart.01117.2009 PubMedCrossRef

22.

Christensen LP, Zhang RL, Zheng W, Campanelli JJ, Dedkov EI, Weiss RM et al (2009) Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. Am J Physiol Heart Circ Physiol 297(1):H322–H330. doi:10.1152/ajpheart.01337.2008

23.

Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E et al (2010) Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology 117(3):234–242. doi:10.1159/000322905 PubMedCrossRef

24.

Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F et al (2004) Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109(13):1674–1679. doi:10.1161/01.cir.0000118464.48959.1c PubMedCrossRef

25.

Fang Y, Debunne M, Vercauteren M, Brakenhielm E, Richard V, Lallemand F et al (2012) Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol 59(3):260–267. doi:10.1097/FJC.0b013e31823e5e01 PubMedCrossRef

26.

Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C (2009) Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 296(2):H435–H441. doi:10.1152/ajpheart.00591.2008 PubMedCrossRef

27.

Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P et al (2011) Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151(2):218–224. doi:10.1016/j.ijcard.2011.06.098 PubMedCrossRef

28.

Ekman I, Chassany O, Komajda M, Bohm M, Borer JS, Ford I et al (2011) Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. Eur Heart J 32(19):2395–2404. doi:10.1093/eurheartj/ehr343 PubMedCrossRef

29.

Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S et al (2010) Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther 15(4):349–355. doi:10.1177/1074248410370326 PubMedCrossRef

30.

Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372(9641):807–816. doi:10.1016/s0140-6736(08)61170-8 PubMedCrossRef

31.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2009) Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 30(19):2337–2345. doi:10.1093/eurheartj/ehp358 PubMedCrossRef

32.

Ceconi C, Freedman SB, Tardif JC, Hildebrandt P, McDonagh T, Gueret P et al (2011) Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol 146(3):408–414. doi:10.1016/j.ijcard.2010.10.125 PubMedCrossRef

33.

Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A et al (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744):875–885. doi:10.1016/s0140-6736(10)61198-1 PubMedCrossRef

34.

Tardif JC, O’Meara E, Komajda M, Bohm M, Borer JS, Ford I et al (2011) Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J 32(20):2507–2515. doi:10.1093/eurheartj/ehr311 PubMedCrossRef

35.

Lage-Galle E, Romero-Rodriguez N, Nevado-Portero J, Guisado-Rasco A, Sobrino-Marquez M, Machuca MG et al (2010) Safety and effectiveness of ivabradine after cardiac transplantation. Transplant Proc 42(8):3191–3192. doi:10.1016/j.transproceed.2010.05.125 PubMedCrossRef

36.

Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L et al (2009) Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 88(6):835–841. doi:10.1097/TP.0b013e3181b4e0f5 PubMedCrossRef

37.

Zhang R, Haverich A, Struber M, Simon A, Pichlmaier M, Bara C (2008) Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 97(11):811–819. doi:10.1007/s00392-008-0690-5 PubMedCrossRef

38.

Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A et al (2007) Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Transplantation 84(8):988–996. doi:10.1097/01.tp.0000285265.86954.80 PubMedCrossRef

39.

Zhang R, Bobylev D, Stiefel P, Haverich A, Bara C (2012) Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study. Clin Res Cardiol. doi:10.1007/s00392-012-0436-2

40.

McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. doi:10.1093/eurheartj/ehs104

41.

Cullington D, Goode KM, Cleland JG, Clark AL (2011) Limited role for ivabradine in the treatment of chronic heart failure. Heart 97(23):1961–1966. doi:10.1136/heartjnl-2011-300041 PubMedCrossRef

42.

Castagno D, Petrie MC, Claggett B, McMurray J (2012) Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure. Eur Heart J 33(9):1137–1141. doi:10.1093/eurheartj/ehs004 PubMedCrossRef

43.

DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320(11):677–683. doi:10.1056/nejm198903163201101 PubMedCrossRef

44.

Gullestad L, Wikstrand J, Deedwania P, Hjalmarson A, Egstrup K, Elkayam U et al (2005) What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). J Am Coll Cardiol 45(2):252–259. doi:10.1016/j.jacc.2004.10.032 PubMedCrossRef

45.

Metra M, Torp-Pedersen C, Swedberg K, Cleland JG, Di Lenarda A, Komajda M et al (2005) Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J 26(21):2259–2268. doi:10.1093/eurheartj/ehi386 PubMedCrossRef

46.

Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M et al (2001) Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 103(10):1428–1433PubMedCrossRef

47.

Gelbrich G, Edelmann F, Inkrot S, Lainscak M, Apostolovic S, Neskovic AN et al (2012) Is target dose the treatment target? Uptitrating beta-blockers for heart failure in the elderly. Int J Cardiol 155(1):160–166. doi:10.1016/j.ijcard.2011.11.018 PubMedCrossRef

48.

McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW (2009) Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 150(11):784–794PubMedCrossRef

49.

Flannery G, Gehrig-Mills R, Billah B, Krum H (2008) Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol 101(6):865–869. doi:10.1016/j.amjcard.2007.11.023 PubMedCrossRef

50.

Huang RL, Listerman J, Goring J, Giesberg C, Nading MA, Butler J (2006) Beta-blocker therapy for heart failure: should the therapeutic target be dose or heart rate reduction? Congest Heart Fail 12(4):206–210 (quiz 211-202)PubMedCrossRef

51.

Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L (2012) Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (systolic heart failure treatment with the I(f) inhibitor ivabradine trial) Study. J Am Coll Cardiol. doi:10.1016/j.jacc.2012.01.020

52.

Cullington D, Goode KM, Clark AL, Cleland JG (2012) Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. doi:10.1093/eurjhf/hfs060

53.

Nagatsu M, Spinale FG, Koide M, Tagawa H, DeFreitas G, Cooper G et al (2000) Bradycardia and the role of beta-blockade in the amelioration of left ventricular dysfunction. Circulation 101(6):653–659PubMedCrossRef

54.

Guth BD, Heusch G, Seitelberger R, Ross J Jr (1987) Mechanism of beneficial effect of beta-adrenergic blockade on exercise-induced myocardial ischemia in conscious dogs. Circ Res 60(5):738–746PubMedCrossRef

55.

Simonsen S, Ihlen H, Kjekshus JK (1983) Haemodynamic and metabolic effects of timolol (Blocadren) on ischaemic myocardium. Acta Med Scand 213(5):393–398PubMedCrossRef

56.

Ulu N, Henning RH, Goris M, Schoemaker RG, van Gilst WH (2009) Effects of ivabradine and metoprolol on cardiac angiogenesis and endothelial dysfunction in rats with heart failure. J Cardiovasc Pharmacol 53(1):9–17. doi:10.1097/FJC.0b013e318193dfce PubMedCrossRef

57.

Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26(23):2529–2536. doi:10.1093/eurheartj/ehi586 PubMedCrossRef

58.

Parakh N, Chaturvedi V, Kurian S, Tyagi S (2012) Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail 18(4):282–288. doi:10.1016/j.cardfail.2012.01.001 PubMedCrossRef

59.

Colin P, Ghaleh B, Hittinger L, Monnet X, Slama M, Giudicelli JF et al (2002) Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol 282(2):H672–H679. doi:10.1152/ajpheart.00547.2001 PubMed

60.

Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R (2011) Efficacy of ivabradine in combination with Beta-blocker versus uptitration of Beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 25(6):531–537. doi:10.1007/s10557-011-6327-3 PubMedCrossRef

61.

Becher PM, Lindner D, Miteva K, Savvatis K, Zietsch C, Schmack B et al (2012) Role of heart rate reduction in the prevention of experimental heart failure: comparison between if-channel blockade and beta-receptor blockade. Hypertension 59(5):949–957. doi:10.1161/hypertensionaha.111.183913 PubMedCrossRef

62.

Riesen SC, Schober KE, Cervenec RM, Bonagura JD (2011) Comparison of the effects of ivabradine and atenolol on heart rate and echocardiographic variables of left heart function in healthy cats. J Vet Intern Med 25(3):469–476. doi:10.1111/j.1939-1676.2011.0705.x PubMedCrossRef

63.

Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G et al (2009) Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail 15(10):856–863. doi:10.1016/j.cardfail.2009.05.013 PubMedCrossRef

64.

Maczewski M, Mackiewicz U (2008) Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 79(1):42–51. doi:10.1093/cvr/cvn057 PubMedCrossRef

65.

Majewski S, Slomka S, Zielinska-Wyderkiewicz E, Ciebiada M, Gorski P (2012) Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study. Am J Cardiovasc Drugs 12(3):179–188. doi:10.2165/11597400-000000000-00000 PubMedCrossRef

66.

Hauptman PJ, Schwartz PJ, Gold MR, Borggrefe M, Van Veldhuisen DJ, Starling RC et al (2012) Rationale and study design of the INcrease Of Vagal TonE in Heart Failure study: iNOVATE-HF. Am Heart J 163(6):954-962 e951. doi:10.1016/j.ahj.2012.03.021 CrossRef

67.

Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K (2004) Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation 109(1):120–124. doi:10.1161/01.cir.0000105721.71640.da PubMedCrossRef

68.

Sabbah HN, Gupta RC, Imai M, Irwin ED, Rastogi S, Rossing MA et al (2011) Chronic electrical stimulation of the carotid sinus baroreflex improves left ventricular function and promotes reversal of ventricular remodeling in dogs with advanced heart failure. Circ Heart Fail 4(1):65–70. doi:10.1161/circheartfailure.110.955013 PubMedCrossRef

69.

De Ferrari GM, Crijns HJ, Borggrefe M, Milasinovic G, Smid J, Zabel M et al (2011) Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. Eur Heart J 32(7):847–855. doi:10.1093/eurheartj/ehq391 PubMedCrossRef

70.

Pfister R, Michels G, Sharp SJ, Luben R, Wareham NJ, Khaw KT (2012) Resting heart rate and incident heart failure in apparently healthy men and women in the EPIC-Norfolk study. Eur J Heart Fail. doi:10.1093/eurjhf/hfs104

71.

Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S, Henneman JA et al (1997) Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS). Circulation 96(7):2197–2205PubMedCrossRef

72.

Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372(9641):817–821. doi:10.1016/s0140-6736(08)61171-x PubMedCrossRef

73.

Ahmadi-Kashani M, Kessler DJ, Day J, Bunch TJ, Stolen KQ, Brown S et al (2009) Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 120(21):2040–2045. doi:10.1161/circulationaha.108.847608 PubMedCrossRef

74.

Chonchol M, Goldenberg I, Moss AJ, McNitt S, Cheung AK (2007) Risk factors for sudden cardiac death in patients with chronic renal insufficiency and left ventricular dysfunction. Am J Nephrol 27(1):7–14. doi:10.1159/000098431 PubMedCrossRef

75.

Opasich C, Rapezzi C, Lucci D, Gorini M, Pozzar F, Zanelli E et al (2001) Precipitating factors and decision-making processes of short-term worsening heart failure despite “optimal” treatment (from the IN-CHF Registry). Am J Cardiol 88(4):382–387PubMedCrossRef

76.

Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB et al (2012) Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in heart failure: assessment of reduction in mortality and morbidity) program. J Am Coll Cardiol 59(20):1785–1795. doi:10.1016/j.jacc.2011.12.044 PubMedCrossRef

Titel: Heart rate reduction in heart failure: ivabradine or beta blockers?
Publikationsdatum: 01.07.2013
Erschienen in: Heart Failure Reviews / Ausgabe 4/2013
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-012-9347-6

Neu im Fachgebiet Kardiologie

25.04.2024 | Hypertonie | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Heart rate reduction in heart failure: ivabradine or beta blockers?

Abstract

Neu im Fachgebiet Kardiologie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Peripheral arterial disease and chronic heart failure: a dangerous mix

The ryanodine receptor leak: how a tattered receptor plunges the failing heart into crisis

Analyzing left ventricular function in mice with Doppler echocardiography

Can parathyroid hormone be used as a biomarker for heart failure?

Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction

Mitochondria in heart failure: the emerging role of mitochondrial dynamics

Neu im Fachgebiet Kardiologie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Update Kardiologie